Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology
October 31, 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Reports Third Quarter 2023 Results
October 26, 2023 07:00 ET
|
Alimera Sciences, Inc.
Net Revenue up 72% to $23.4 Million vs. Q3 2022Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022Adjusted EBITDA of $5.4 Million in Q3 2023Successful Integration of YUTIQ into the U.S. Segment ...
Alimera Sciences to Report Third Quarter 2023 Financial Results on October 26, 2023, and Provide Corporate Update
October 16, 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
October 11, 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
October 03, 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners...
Alimera Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Sciences Reports Second Quarter 2023 Results
August 10, 2023 07:30 ET
|
Alimera Sciences, Inc.
Alimera Acquired U.S. Commercial Rights to YUTIQ®Landmark NEW DAY Study Completed Enrollment with over 300 PatientsConsolidated Net Revenue of $17.5 Million Up 20% vs. Second Quarter of 2022Global End...
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
August 02, 2023 11:43 ET
|
Alimera Sciences, Inc.
ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Completes Recruitment for its Landmark NEW DAY Study
May 24, 2023 08:00 ET
|
Alimera Sciences, Inc.
ATLANTA, May 24, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners...
Alimera Acquires U.S. Commercial Rights to YUTIQ®
May 18, 2023 07:00 ET
|
Alimera Sciences, Inc.
Expected to be immediately accretive to revenue and Adjusted EBITDA in 2023 Alimera projects at least $100 million of consolidated net revenue and over $20 million of Adjusted EBITDA* in 2024...